MOXIe… A clinical study designed for patients with Friedreich’s ataxia
MOXIe is a Phase 2 clinical study evaluating the safety and effectiveness of omaveloxolone (an oral investigational drug) for the treatment of Friedreich’s ataxia.
You may be eligible for this study if you:
- Are 16 to 40 years of age
- Have been genetically diagnosed with Friedreich’s ataxia
- Are willing to maintain a consistent exercise routine and stable medication doses throughout the study
- Are willing to discontinue taking certain antioxidant supplements and vitamins, or any other medication intended to treat Friedreich’s ataxia, before beginning this study and throughout your participation in the study
Other eligibility criteria will apply.
To see if you pre-qualify for MOXIe